Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

AbbVie (NY: ABBV )

171.73 +3.97 (+2.37%)
Official Closing Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,847,727
Open 168.59
Bid (Size) 171.50 (1)
Ask (Size) 172.26 (1)
Prev. Close 167.76
Today's Range 166.92 - 172.46
52wk Range 137.65 - 207.32
Shares Outstanding N/A
Dividend Yield 3.61%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Unpacking the Latest Options Trading Trends in AbbVie
Via Benzinga
What To Do After The Worst Week For Healthcare Stocks Since March 2020?
The market was quiet today but we should still expect some gains through year -end albeit a bit choppy. 
Via Talk Markets

Performance

YTD
+7.45%
+7.45%
1 Month
-9.02%
-9.02%
3 Month
-12.55%
-12.55%
6 Month
+8.51%
+8.51%
1 Year
+24.02%
+24.02%

More News

Read More
Where Will AbbVie Be in 5 Years?
Via The Motley Fool
Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip
Via The Motley Fool
Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers
Via Benzinga
AbbVie, Bitcoin And An Energy Stock On CNBC's 'Final Trades'
Via Benzinga
Smart Money Is Betting Big In ABBV Options
Via Benzinga
Seeking Beta
Via Talk Markets
Navigating 14 Analyst Ratings For AbbVie
Via Benzinga
Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock
Via The Motley Fool
Abbvie Stock Price Analysis – A Post-Humira Dip, New Drug Hopes, And Election Buzz – Is Now The Time To Buy?
Via Talk Markets
Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom
Via Benzinga
AbbVie Stock Drops 12% On Schizophrenia Drug Setback: Should You Buy The Dip?
Via Talk Markets
This Is What Whales Are Betting On AbbVie
Via Benzinga
2 Dividend Stocks to Buy Hand Over Fist in November
Via The Motley Fool
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
Via Benzinga
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
Via Benzinga
Biotech Stocks Are Rallying: What Is Your Playbook?
Via Talk Markets
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why AbbVie Stock Was Getting Mashed on Monday
Via The Motley Fool
What's Going On With Bristol-Myers Squibb Shares Monday?
Via Benzinga
AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated
Via Benzinga
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges
Via Benzinga
Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails
Via Investor's Business Daily
3 Spectacular High-Yield Dividend Stocks to Buy in November
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.